74 activities found

Key Insights: Great Debates & Updates in Hematologic Malignancies 2016

The continued evolution and refinement of strategies for disease diagnosis, risk assessment, therapeutic intervention and disease management have provided patients with hematologic malignancies and benign hematologic disorders with enhanced outcomes and improved quality of life. The 2016 Great Debates & Updates in Hematologic Malignancies conference, held April 1-2 in New York, NY, provided clinicians with the most current and pertinent data in the areas of multiple myeloma (MM), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute leukemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), lymphoma and benign hematology. This Key Insights™ activity provides a summary of the key "take-home" points from the meeting.
0.75 CME

Webcast: Great Debates & Updates in GI Malignancies 2016

There have been tremendous advancements in the multidisciplinary management of GI cancers in the past decade, with a growing number of new and improved targeted agents and efficacious combination regimens yielding substantial clinical benefits in both early and late stages of the diseases. Moreover, breakthroughs in molecular profiling, cancer immunology, early stage detection, and novel diagnostic techniques have led to accelerated strides in GI cancer research and management. As the field of GI malignancies is continuously evolving, community oncologists must strive to keep abreast of the latest developments and resolve new issues in optimizing the management of esophageal, gastric, hepatocellular, pancreatic, and colorectal cancers. To this end, this webcast highlights the clinically significant information presented during the 2016 Great Debates and Updates in GI Malignancies in New York, New York from April 1-2, 2016.
8 CME

Key Insights: Great Debates & Updates in Inflammatory Bowel Disease 2016 - Adult Session

This Key Insights activity serves to provide a brief synopsis of the key points presented on inflammatory bowel diseases at the Great Debates and Updates in Inflammatory Bowel Disease conference held in San Francisco, California from March 18-19, 2016. Dr. Marla Dubinsky’s expert review moderated by Dr. Joel Rosh covers recent developments in counseling of pregnant patients, psychosocial care, health maintenance, treat to target. management of post-operative IBD, and malignancy.
0.5 CME

Key Insights: Great Debates & Updates in Inflammatory Bowel Disease 2016 - Pediatric Session

This Key Insights activity serves to provide a brief synopsis of the key points presented on pediatric inflammatory bowel diseases at the Great Debates and Updates in Inflammatory Bowel Disease held in San Francisco, California from March 18-19, 2016. Dr. Joel Rosh’s expert review moderated by Dr. Marla Dubinsky covers recent developments in diagnosis, phenotyping and risk stratification, epidemiology, environment and pathogenesis of IBD, mucosal healing as a treatment target, optimization of therapy and perianal Crohn’s disease and pouch complications.
0.5 CME

Key Insights: 13th Annual Best of San Antonio - Breast Cancer: Bench to Bedside

Advancements in breast cancer care continue to rapidly evolve and the San Antonio Breast Cancer Symposium (SABCS) is the premier annual forum for exchange of new scientific and clinical information. However, not all healthcare professionals have the opportunity to attend this meeting and even those that do attend often can benefit from taking a deeper dive into the relevance of the data in a smaller venue in which more intimate faculty and peer interactions can take place. This is the role of the annual Best of San Antonio - Breast Cancer: Bench to Bedside meeting—to help practicing clinicians interpret the most clinically-relevant data presented during the SABCS and apply it in their practice of caring for patients with breast cancer. This webcast features Chair, Kathy Albain, MD, FACP, FASCO discussing highlights from the 13th Annual Best of San Antonio - Breast Cancer: Bench to Bedside.
1 CME

Key Insights: 17th European Congress: Perspectives in Lung Cancer

This Key Insights activity serves to provide a brief synopsis of the key points presented on thoracic oncology at the 17th European Congress: Perspectives in Lung Cancer held in Prague, Czech Republic from 4-5 March 2016. Dr. Giorgio V. Scagliotti's expert review covers recent developments in novel strategies for early-stage NSCLC, the continuously evolving role of molecular and histology testing to individualize therapy, recent developments in immunotherapy, and emerging data regarding novel treatment strategies for patients with metastatic NSCLC.
0.25 CME

Interactive Case: JAK Inhibitors for the Successful Management of Polycythemia Vera

Polycythemia vera (PV) is characterized by erythrocytosis, thrombocytosis, and/or leukocytosis with a broad-range of disease-related symptoms that impact the overall health and everyday quality of life of patients. The identification of the high frequency JAK2V617F mutation in patients with PV defines a molecular target for therapeutic intervention. This interactive case-based activity, is designed to complement, accelerate, and reinforce application of knowledge and skills amongst healthcare professionals interested in optimal management strategies for patients with PV.
0.5 CME

Expert Perspectives: Rationale for CDK 4/6 Inhibition in Breast Cancer

The cyclin-dependent kinase (CDK) pathway is critical to cell cycle entry. In many tumor types, including breast cancer, there is dysregulation of this pathway. This activity describes the rationale and mechanism for inhibiting this dysregulated pathway in estrogen receptor-positive (ER+) metastatic breast cancer using selective CDK 4/6 inhibitors.
0.25 CME

Expert Perspectives: CDK 4/6 Inhibitors for ER+ Breast Cancer: Current Data and Clinical Use

Cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with antiestrogen therapy work to combat endocrine resistance in women with estrogen ER+ metastatic breast cancer. One CDK 4/6 inhibitor is FDA approved and 2 others are in Phase 3 development for breast cancer. This activity discusses clinical data on the efficacy and safety of the FDA-approved CDK 4/6 inhibitor, palbociclib, in combination with letrozole in ER+ metastatic breast cancer.
0.5 CME

Expert Perspectives: CDK 4/6 Inhibitors for ER+ Breast Cancer: Emerging Data and Future Implications

Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors in combination with antiestrogen therapy work to combat endocrine resistance in women with estrogen receptor-positive (ER+) metastatic breast cancer. One CDK 4/6 inhibitor is FDA approved and 2 others are in Phase 3 development for this use. This activity discusses the ongoing and planned clinical trials for abemaciclib and ribociclib in ER+ metastatic breast cancer, as well as the future implications for this class of agents in this patient population.
0.25 CME